Warren Buffett, Donald Trump Bet on Same 17 Stocks — Some Might Surprise You
The investment portfolio of President Donald Trump and Berkshire Hathaway have 17 stocks in common. Here's a look at the list.
Stocks · News reference
DaVita Enters Value-Based Care Agreement With Humana Medicare Advantage To Provide Care To Members With Chronic Kidney Disease Stages 3B–5
Launched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the greatest impact.As
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
DaVita Reaches Preliminary Settlement Class Agreement Following Ransomware Attack
A federal court preliminarily approves a class action settlement for 2.3 million patients affected by the DaVita ransomware attack.
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
Fresenius Medical Care is scaling up its 5008X CAREsystem rollout, converting 227 U.S. clinics to the new technology by July 2026, representing 10% of its machine base. The company has performed over 600,000 treatments including 100,000+ high-volume hemodiafiltration treatments, showing clinical promise with 40% fewer muscle cramps. However, near-term headwinds include weak U.S. treatment volume growth (-0.9%), TDAPA reimbursement pressure (€50 million drag expected), and significant rollout implementation costs.
Berkshire Hathaway Cut Capital One Stake by 58% in Q2 — Billionaire Dan Loeb Is Doing the Exact Opposite
Berkshire slashed its Capital One stake by 58%, among its largest cuts, despite the stock's top growth score.
This 3M Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
Analysts upgraded First Financial, 3M, Synopsys, Humana and Stem, raising targets for four while maintaining Stem’s $7 target.
Humana shares are trading higher after Barclays upgraded its rating on the stock from Equal-Weight to Overweight and raised its price target from $407 to $515.